Page last updated: 2024-10-31

midazolam and Experimental Neoplasms

midazolam has been researched along with Experimental Neoplasms in 1 studies

Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Xu, J1
Li, H1
Wang, X1
Huang, J1
Li, S1
Liu, C1
Dong, R1
Zhu, G1
Duan, C1
Jiang, F1
Zhang, Y1
Zhu, Y1
Zhang, T1
Chen, Y1
Tang, W1
Lu, T1

Other Studies

1 other study available for midazolam and Experimental Neoplasms

ArticleYear
Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity.
    European journal of medicinal chemistry, 2020, Aug-15, Volume: 200

    Topics: Animals; Antineoplastic Agents; Cell Proliferation; Coumarins; Cyclin-Dependent Kinase 9; Dose-Respo

2020